DAMORA THERAPEUTICS, INC. (DMRA) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -270.66M USD | Operating Income (Loss) |
| Revenue | (m) | |
| Cost of products and services | (m) | |
| Research and development | 74.05M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-270.66M | (m) | (m) | $74.05M | (m) | (m) |
| 2026-03-31 | $-239.08M | (m) | (m) | $49.98M | (m) | (m) |
| 2025-12-31 | $-210.87M | (m) | (m) | $26.88M | (m) | (m) |
| 2025-09-30 | $-16.28M | (m) | (m) | $4.57M | (m) | (m) |
| 2025-06-30 | $-16.96M | (m) | (m) | $4.24M | (m) | (m) |
| 2025-03-31 | $-19.12M | (m) | (m) | $4.61M | (m) | (m) |
| 2024-12-31 | $-22.26M | (m) | (m) | $6.40M | (m) | (m) |
| 2024-09-30 | $-21.83M | (m) | (m) | $8.16M | (m) | (m) |
| 2024-06-30 | $-26.57M | (m) | (m) | $9.62M | (m) | (m) |
| 2024-03-31 | $-32.15M | (m) | (m) | $15.87M | (m) | (m) |
| 2023-12-31 | $-39.91M | (m) | (m) | $23.77M | (m) | (m) |
| 2023-09-30 | $-46.76M | (m) | (m) | $31.77M | (m) | (m) |
| 2023-06-30 | $-51.80M | (m) | (m) | $39.72M | (m) | (m) |
| 2023-03-31 | $-57.76M | (m) | (m) | $45.33M | (m) | (m) |
| 2022-12-31 | $-61.21M | (m) | (m) | $48.21M | (m) | (m) |
| 2022-09-30 | $-61.15M | (m) | (m) | $47.55M | (m) | (m) |
| 2022-06-30 | $-60.47M | (m) | (m) | $46.80M | (m) | (m) |
| 2022-03-31 | $-55.61M | (m) | (m) | $41.73M | (m) | (m) |
| 2021-12-31 | $-52.23M | (m) | (m) | $38.49M | (m) | (m) |
| 2021-09-30 | $17.21M | (m) | (m) | $36.13M | (m) | (m) |
| 2021-06-30 | $19.98M | (m) | (m) | $34.03M | (m) | (m) |
| 2021-03-31 | $25.91M | (m) | (m) | $29.91M | (m) | (m) |
| 2020-12-31 | $33.64M | (m) | (m) | $24.63M | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $38.97M | (m) | (m) | $19.74M | (m) | (m) |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |